Earnings summaries and quarterly performance for Sunshine Biopharma.
Executive leadership at Sunshine Biopharma.
Board of directors at Sunshine Biopharma.
Research analysts covering Sunshine Biopharma.
Recent press releases and 8-K filings for SBFM.
Sunshine Biopharma Subsidiary Receives Health Canada Approval for Domperidone
SBFM
Product Launch
New Projects/Investments
Profit Warning
- Sunshine Biopharma's subsidiary, Nora Pharma, has received Health Canada approval to commercialize Domperidone, a prescription drug used to treat nausea and vomiting, marking its entry into the Canadian pharmaceutical market.
- The North American Domperidone market is projected to reach $533 million in 2025.
- The company currently has 76 generic prescription drugs in Canada and plans to launch more than 12 additional drugs in 2026.
- Financially, Sunshine Biopharma has a market capitalization around $9.6 million, faces negative earnings, and has an Altman Z-Score of -0.93, indicating distress and potential bankruptcy risk within two years.
- Insider ownership is significant at 24.07%, reflecting confidence in the company's strategic direction despite low institutional ownership.
Oct 28, 2025, 12:16 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more